Paliperidone +pharma, (Paliperidone Palmitate)

Paliperidone Palmitate, the active ingredient in Paliperidone +pharma, is a atypical antipsychotic presented as a long‑acting injectable suspension for intramuscular use. It is indicated for the treatment of schizophrenia in adult patients. GNH USA supplies Paliperidone +pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Paliperidone +pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidone Palmitate is an atypical antipsychotic that modulates dopamine and serotonin activity in schizophrenia.

- Schizophrenia: Improves psychotic symptoms and reduces risk of relapse. - Schizoaffective disorder: Stabilises mood and psychotic features. - Bipolar I disorder (maintenance): Provides long‑term mood stabilization when oral therapy is insufficient.

Adverse reactions to Paliperidone Palmitate vary in frequency and severity.

Common Side Effects: - Injection site pain - Headache - Akathisia - Restlessness - Insomnia - Weight gain

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Tardive dyskinesia - Severe hypotension - Seizures - Hyperglycaemia - Elevated prolactin levels.

When prescribing Paliperidone + pharma, clinicians should consider several clinical aspects:

- Assess risk of cardiovascular events : Review electrocardiogram findings and monitor blood pressure and heart rate. - Monitor metabolic parameters : Check fast‑fats fast r  ... -  ... ... ... ... ... ... ... ... ...  ... ...  ...

This ... … …… ... 

....